A new, compact synthesizer of PET radiotracers -- about a third the size of systems currently available -- is poised to enter the U.S. market later this year. Hear an interview with its inventor, Maxim Kiselev, Ph.D., vice president of R&D for IBA Molecular.
A new, compact synthesizer of PET radiotracers - about a third the size of systems currently available - is poised to enter the U.S. market later this year. Synthera, developed by IBA (Ion Beam Applications) Molecular and priced at about $96,000, was unveiled at the Society of Nuclear Medicine meeting June 3 to 7 in San Diego. Its core component, the ejectable Integrated Fluidic Processor, makes it a true multirun system capable of producing various radiotracers, including FDG, according to its inventor, Maxim Kiselev, Ph.D., vice president of R&D for IBA Molecular. (hear a two-minute interview with Kiselev from the SNM exhibit floor)
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.